Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Stefan K AligCharles W MacaulayDavid M KurtzUlrich DührsenAndreas HuettmannChristine SchmitzMichael C JinBrian J SworderAndrea GarofaloMohammad Shahrokh EsfahaniBarzin Y NabetJoanne SooFlorian SchererAlexander F M CraigRené-Olivier CasasnovasJason R WestinGianluca GaidanoDavide RossiMark J RoschewskiWyndham H WilsonMichel MeignanMaximilian DiehnAsh A AlizadehPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Short DTI largely reflects baseline tumor burden, which can be objectively measured using pretreatment ctDNA levels. Pretreatment ctDNA levels therefore have utility for quantifying and guarding against selection biases in prospective DLBCL clinical trials.